Slowly Expanding Lesions Differentiate Pediatric Multiple Sclerosis from Myelin Oligodendrocyte Glycoprotein Antibody Disease

Giulia Fadda; Brenda Banwell; Colm Elliott; Dumitru Fetco; Douglas L Arnold; Patrick Waters; E Ann Yeh; Ruth Ann Marrie; Amit Bar-Or; Sridar Narayanan; Canadian Pediatric Demyelinating Disease Network

doi:10.1002/ana.27066

Slowly Expanding Lesions Differentiate Pediatric Multiple Sclerosis from Myelin Oligodendrocyte Glycoprotein Antibody Disease

Ann Neurol. 2024 Dec;96(6):1086-1091. doi: 10.1002/ana.27066. Epub 2024 Sep 7.

Authors

Giulia Fadda¹, Brenda Banwell², Colm Elliott³, Dumitru Fetco^{3

4

5}, Douglas L Arnold^{3

4

5}, Patrick Waters⁶, E Ann Yeh⁷, Ruth Ann Marrie⁸, Amit Bar-Or⁹, Sridar Narayanan^{3

4

5}; Canadian Pediatric Demyelinating Disease Network

Affiliations

¹ Department of Medicine, University of Ottawa, Ottawa Hospital Research Institute, Ottawa, ON, Canada.
² Department of Neurology, The Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
³ NeuroRx Research, Montreal, QC, Canada.
⁴ Department of Neurology and Neurosurgery, McGill University, Montreal, QC, Canada.
⁵ McConnell Brain Imaging Center, Montreal Neurological Institute-Hospital, McGill University, Montreal, QC, Canada.
⁶ Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, University of Oxford, Oxford, UK.
⁷ Department of Pediatrics, University of Toronto, Toronto, ON, Canada.
⁸ Department of Community Health Sciences, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada.
⁹ Center for Neuroinflammation and Neurotherapeutics, and Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.

PMID: 39243229
DOI: 10.1002/ana.27066

Abstract

Slowly expanding lesions (SELs) in adults with multiple sclerosis (MS) indicate a progressive pathological process. Whether SELs are present in pediatric-onset MS (POMS) or myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is unknown. We studied 19 children with POMS and 14 with MOGAD (median age 14.3 and 9.4 years, respectively) recruited to the Canadian Pediatric Demyelinating Disease Study with: (1) ≥3 research scans 12 months apart; and (2) ≥1 T2-lesions on the earliest scan. A total of 70 SELs from 16 POMS participants and 1 SEL in the MOGAD group were detected. SELs are an early feature of POMS and essentially not a feature of MOGAD. ANN NEUROL 2024;96:1086-1091.

MeSH terms

Adolescent
Autoantibodies / blood
Child
Demyelinating Autoimmune Diseases, CNS / diagnostic imaging
Demyelinating Autoimmune Diseases, CNS / immunology
Diagnosis, Differential
Disease Progression
Female
Humans
Magnetic Resonance Imaging / methods
Male
Multiple Sclerosis* / diagnostic imaging
Multiple Sclerosis* / immunology
Myelin-Oligodendrocyte Glycoprotein* / immunology

Substances

Myelin-Oligodendrocyte Glycoprotein
Autoantibodies

Grants and funding

Multiple Sclerosis Scientific Research Foundation (Canada)